Ireland - English - HPRA (Health Products Regulatory Authority)

maco pharma (uk) ltd - potassium chloride; sodium chloride; glucose monohydrate - solution for infusion - 0.3/0.18/4 %w/v - electrolytes with carbohydrates

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), sodium sulfate (unii: 0ypr65r21j) (sodium sulfate anhydrous - unii:36kcs0r750), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid for oral solution is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults. peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid for oral solution is contraindicated in the following conditions: -   gastrointestinal (gi) obstruction [see warnings and precautions (5.6)] -   bowel perforation [see warnings and precautions (5.6)] -   gastric retention -   ileus -   toxic colitis or toxic megacolon -   hypersensitivity to any ingredient in peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid for oral solution [see warnings and precautions (5.10)] risk summary there are no available data on peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid for oral solution in pregnant women to inform a drug-associated risk for adverse developmental

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sodium nitroprusside, quantity: 50 mg - injection, solution - excipient ingredients: water for injections - dbl? sodium nitroprusside injection is indicated for:,1. immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside.,2. producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate.,3. short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.

Ireland - English - HPRA (Health Products Regulatory Authority)

maco pharma (uk) ltd - potassium chloride, sodium chloride - solution for infusion - 0.2/0.9 %w/v - solutions affecting the electrolyte balance

Ireland - English - HPRA (Health Products Regulatory Authority)

maco pharma (uk) ltd - potassium chloride; sodium chloride - solution for infusion - 0.15/0.9 %w/v - electrolytes

Ireland - English - HPRA (Health Products Regulatory Authority)

maco pharma (uk) ltd - potassium chloride; sodium chloride; glucose monohydrate - solution for infusion - 0.15 0.18 4 %w/v - electrolytes with carbohydrates

Israel - English - Ministry of Health

teva medical marketing ltd. - sodium chloride - solution for infusion - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

Israel - English - Ministry of Health

teva medical marketing ltd. - sodium chloride - solution for infusion - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

Ireland - English - HPRA (Health Products Regulatory Authority)

b. braun medical limited - sodium chloride; potassium chloride; sodium lactate solution; calcium chloride dihydrate - solution for infusion - per cent - solutions affecting the electrolyte balance; electrolytes

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.